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Defective p53 antiangiogenic signaling in glioblastoma
Abstract
Previous findings suggest an angiogenesis-regulating function of the p53 tumor suppressor protein in
various malignancies. With several antiangiogenic agents entering the clinic, we assessed the value of
the TP53 status in predicting angiogenesis in glioblastoma in vivo and examined underlying
angiogenic-signaling pathways in vitro. We identified 26 TP53 wild-type and 9 TP53 mutated
treatment-naïve, primary, isocitrate dehydrogenase 1 (IDH1) wild-type glioblastoma specimens by
sequence analysis and quantified vascularization. P53 responsiveness of the angiogenesis-related target
genes, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF),
thrombospondin 1 (TSP-1), brain-specific angiogenesis inhibitor 1 (BAI1), and collagen
prolyl-4-hydroxylase alpha 2 (P4HA2), was evaluated by (i) overexpression of wild-type p53 in
homozygously TP53-deleted LN-308 cells; (ii) shRNA-mediated p53 knockdown in the TP53 wild-type
LNT-229 cells; and (iii) chemical induction of wild-type p53 expression in LNT-229 cells by
camptothecin. Irrespective of the TP53 status, vascularization did not differ significantly between the
two groups of glioblastoma specimens. Of all target genes, only P4HA2 mRNA was upregulated
through wild-type p53. As opposed to several nonglial tumors, in glioblastoma cells, p53-mediated
transcriptional induction of P4HA2 mRNA neither resulted in increased levels of P4HA2 protein or
antiangiogenic endostatin nor did it influence endothelial cell sprouting, viability, or transmigration in
vitro. Moreover, p53-uncoupled stable overexpression of P4HA2 in LN-308 cells did not affect
endothelial cell viability. These data challenge the view of p53 as an angiogenesis-regulator in
glioblastoma in that relevant signaling pathways are silenced, potentially contributing to the angiogenic
switch during malignant progression.
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Abstract 
Previous findings hint at a potential angiogenesis-regulating function of the p53 tumor 
suppressor protein in various malignancies. With the antiangiogenic agents currently being 
under clinical investigation, we assessed the value of p53 in predicting angiogenesis in 
glioblastoma and examined potential underlying angiogenic signaling pathways. We 
identified 26 TP53 wild-type and 9 TP53 mutated treatment-naïve, primary, isocitrate 
dehydrogenase 1 (IDH1) wild-type glioblastoma specimens by sequence analysis, and 
quantitated vascularization using automated image analysis of CD31-immunoreactive tumor 
vessels. For signaling analyses, we analyzed the p53-inducibility of known angiogenesis-
related target genes, vascular endothelial growth factor (VEGF), basic fibroblast growth 
factor (bFGF), thrombospondin 1 (TSP1), brain-specific angiogenesis inhibitor 1 (BAI1), and 
collagen prolyl-4-hydroxylase alpha 2 (P4HA2), using three different approaches: i) stable 
overexpression of wild-type p53 in the homozygously TP53-deleted human glioblastoma cell 
line LN-308; ii) shRNA-mediated p53 knock-down in the TP53 wild-type glioblastoma cell line 
LNT-229; and iii) chemical induction of wild-type p53 expression in LNT-229 cells by the 
DNA-damaging agent camptothecin. We found that, irrespective of the underlying TP53 
status, vascularization did not differ significantly between glioblastoma specimens. Unlike 
other candidate factors, only P4HA2 mRNA became robustly upregulated through wild-type 
p53. As opposed to several non-glial tumors, in glioblastoma cells, p53-mediated 
transcriptional induction of P4HA2 mRNA was neither paralleled by increased P4HA2 protein 
and endostatin concentrations nor influenced endothelial cell function in vitro. Moreover, p53-
uncoupled stable overexpression of P4HA2 in LN-308 cells did not affect endothelial cell 
function either. In conclusion, our data challenge the view of p53 as an angiogenesis-
regulating molecule in glioblastoma in that relevant signaling pathways are transcriptionally, 
translationally and post-translationally shut down potentially contributing to the angiogenic 
switch during malignant progression. 
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Introduction 
The tumor vasculature of glioblastomas has long been recognized as a promising therapeutic 
target, and consequently, a number of antiangiogenic treatment regimens have currently 
been under clinical investigation recently leading to the approval of bevacizumab for 
recurrent glioblastomas.1-5 Identifying and establishing angiogenesis-related molecular 
alterations as diagnostic, prognostic or predictive biomarkers as well as potential stratification 
factors will therefore be essential for future clinical trials that test antiangiogenic or vessel-
modifying agents, and for selecting patient subpopulations in whom an antiangiogenic-based 
regimen will be beneficial. 
The most devastating glioma grade, glioblastomas are highly vascularized malignancies, and 
the presence of microvascular proliferation is a key feature for their diagnosis.6 Tumor 
angiogenesis is fundamental to the propagation of glioblastomas as it results in the formation 
of new blood vessels providing supply of oxygen and nutrients to cells when the tumor size 
exceeds a few millimeters in diameter.7 The process of angiogenesis is tightly governed by a 
balance between pro- and antiangiogenic factors that regulate the growth of endothelial cells, 
the cellular precursors of blood vessels. Remarkably, as vessel formation is most required by 
rapidly growing tissues such as cancers, growth-promoting factors, i.e. oncogenes, 
frequently induce or propagate angiogenesis whereas tumor suppressor genes are often 
likely to contribute to the inhibition of angiogenesis.8 
Since its discovery in 1979, extensive research into the role of TP53 has revealed its function 
as a multimodally acting tumor suppressor being the most frequently altered gene in human 
cancers and mutationally inactivated in half of all tumors.9,10 Basal activities of wild-type p53 
become markedly increased in response to oncogenic signaling and stress or damage 
signals. The crucial tumor suppressive function of p53 is impressively documented by the 
phenotype of the first Trp53 knockout mouse that, after developing normally, had early 
spontaneous tumors of various types.11 The p53 protein functions, at least in part, as a 
transcription factor controlling the expression of target genes that act at most steps in cancer 
biology, predominantly concerning cell cycle arrest, DNA repair, and apoptosis.12 In addition 
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to these classical ‘genome-guarding’ roles, p53 has also been attributed to an angiogenesis-
controlling function as supported by findings from clinical studies in various human 
carcinomas demonstrating that tumors carrying p53 mutations were more highly vascularized 
than tumors harboring wild-type p53.13-18 In vitro work on the molecular linkage between p53 
and the regulatory pathways of angiogenesis has since discovered three basic mechanisms 
underlying the angiogenesis-limiting effects of wild-type p53: (1) interference with hypoxia-
induced factor (HIF)-1 as a central responder to hypoxia and potent promoter of 
angiogenesis, (2) downregulation of proangiogenic factors, e.g. vascular endothelial growth 
factor (VEGF) or basic fibroblast growth factor (bFGF), and (3) upregulation of endogenous 
angiogenesis inhibitors, e.g. thrombospondin-1 (TSP-1), brain-specific angiogenesis inhibitor 
1 (BAI1), 1 collagen 18 (COL18A1), 1 collagen 4 (COL4A1), or collagen prolyl hydroxylase 
2 (P4HA2).19 
Mutations of the TP53 gene occur as early events in two-thirds of precursor low-grade diffuse 
astrocytomas and play a crucial role in the development of secondary glioblastomas derived 
thereof, whereas, in primary, i.e. de novo glioblastomas, TP53 mutations are detected at a 
considerably lower frequency (<30% of cases).20 The goal of the present study was to define 
the value of the TP53 mutational status in indicating the extent of vascularization in 
glioblastoma, analyze potentially underlying angiogenic signaling pathways, and thus identify 
glioblastoma subgroups that are likely to respond differentially towards antiangiogenic 
treatment. 
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Materials and Methods 
Glioblastoma specimens and vessel quantitation 
For analyses of TP53 mutations, 40 previously untreated primary glioblastomas with 
available tumor tissue of at least one cm in diameter were included. All cases were 
diagnosed at the Department of Neuropathology, University Hospital Heidelberg, Germany. 
Informed consent for molecular analysis was given by the patient. DNA was isolated from 
paraffin tissue and analyzed for TP53 mutations in exons 5a, 5b, 6, 7 and 8 as previously 
described.21 To exclude glioblastomas with the genetic profile of secondary glioblastomas, 
we screened for the most frequent isocitrate dehydrogenase 1 (IDH1) mutation (R132H) with 
IDH1 mutation specific antibody mIDH1R132H as recently described.22 Specimens with 
conclusive sequencing of TP53 and negative mIDH1R132H immunostaining were further 
analyzed for vascularization. 
To minimize observer bias, analysis of vascularization was performed by the following 
predefined criteria. For all specimens selected for vessel quantitation (n=35), consecutive 
sections stained for hematoxylin and eosin (H&E), proliferation marker Ki-67 (clone MIB1, 
dilution 1:100; Dako Denmark A/S, Glostrup, Denmark) and endothelial marker CD31 (clone 
JC70A, dilution 1:10; Dako) were prepared according to routine protocols. H&E-stained 
slides were evaluated to identify regions consisting of solid tumor tissue distant from 
necroses. Within these tumor regions, the region of highest proliferation marked by positive 
Ki-67 staining was determined in each specimen as observed under a light microscope and 
marked on the glass slides. The markings were transferred to CD31-immunostained slides 
and one random photomicrograph of the marked area was taken at 100-fold magnification on 
a Zeiss Axioplan2 microscope (Zeiss, Jena, Germany) with a Zeiss AxioCam color digital 
camera. The investigator (D.C.) was blinded for the results of the TP53 mutation analyses 
until photomicrographs were taken and submitted for analysis. Unprocessed Tagged Image 
File (tif) photomicrographs were then analyzed by an automated image analysis algorithm 
provided by S.CO for vascularity (S.CO LifeScience Company, Garching, Germany). The 
image analysis provides data of total area and total number of vascular structures. 
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Reagents, cell culture and transfections 
The human malignant glioma cell lines LN-308 and LN-229 were kindly provided by Dr. N. de 
Tribolet (Lausanne, Switzerland). The p53 status of these cells was assessed previously.23 
Importantly, LN-229 cells still harbor the wild-type TP53 gene and were therefore renamed 
LNT-229 (T for Tübingen) for clarification. The non-small cell lung carcinoma cell line H1299 
was received by courtesy of Michael R. Green, University of Massachusetts Medical School, 
Worcester, MA, USA.24 Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 4.5g/l glucose, 2 mM glutamine and 0.1 mg/l Fe(III)-nitrate-9-hydrate (PAA 
Laboratories, Pasching, Austria), supplemented with 10% fetal bovine serum (FBS) (Perbio, 
Bonn, Germany), 100 IU/ml penicillin (PAA Laboratories), 100 mg/ml streptomycin (PAA 
Laboratories), and 100 µM ascorbic acid (Sigma-Aldrich). Primary human umbilical vein 
endothelial cells (HUVEC) were purchased from PromoCell (Heidelberg, Germany) and kept 
in endothelial cell growth medium (ECGM) supplemented with Supplement Mix C-39215 
(Promocell), 10% FBS, 100 IU/ml penicillin and 100 mg/ml streptomycin. HUVEC were only 
used between passages three and five. Human cerebral microvascular endothelial cells 
(hCMEC) were kindly provided by F. Miller (Institut Cochin, Paris, France) and grown in 
EBM-2 (Lonza, Basel, Switzerland) supplemented with EGM-2 MV SingleQuots (Lonza), 
HEPES (PAA Laboratories), 100 IU/ml penicillin and 100 mg/ml streptomycin in cell culture 
dishes coated with rat tail collagen I (BD, Heidelberg, Germany). For experiments, hCMEC 
were only used between passages 27 and 32. Cells were cultured at 37°C, 5% CO2 and 21% 
O2. All cell cultures were routinely tested for contamination with Mycoplasma as described 
previously.25 
Chemical induction of p53. For chemical induction of p53, LNT-229 cells were treated with 1, 
10 and 100 nM of the DNA-damaging agent camptothecin (BioVision, Mountain View, CA, 
USA) or dimethyl sulfoxide (DMSO) as a vehicle control and harvested 36 h thereafter. 
Transient overexpression of p53. p53-overexpressing cells were generated by transiently 
transfecting LN-308 and H1299 cells with the expression vector pcDNA3 (Invitrogen, 
Carlsbad, CA, USA) containing either cDNA encoding human p53 wild-type or no insert 
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DNA26 using the FuGENE® HD transfection reagent (Roche, Mannheim, Germany) with the 
provided protocol. 
p53 silencing. LNT-229 p53 knock-down cells were described before23 and cultured in 
puromycin-containing medium (10 µg/ml) (Sigma-Aldrich, Steinheim, Germany). 
Stable overexpression of P4HA2. H1299 cells with stably integrated P4HA2-encoding or no 
insert cDNA-containing p3xFLAG-myc-CMV-26 (Sigma-Aldrich) expression vectors were 
kindly provided by Michael R. Green, University of Massachusetts Medical School, 
Worcester, MA, USA.24 Glioma cells stably overexpressing P4HA2 and empty vector control 
cells, respectively, were generated by transfecting LN-308 cells with either vectors using 
FUGENE® HD and selecting with 700 µg/ml G418 (Sigma-Aldrich). 
 
Quantitative reverse transcription polymerase chain reaction 
For isolation of total RNA, cells were cultured for 48 h and harvested according to the Qiagen 
RNAeasy RNA isolation kit (Qiagen, Hilden, Germany). cDNA synthesis was carried out 
following the instructions of the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA, USA). Quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) was performed in an ABI 7000 thermal cycler using the SYBR Green 
PCR Mastermix (Applied Biosystems) according to standard protocols. Reactions were 
checked by including no-RT-controls, by omission of templates, and by both melting curve 
and gel analysis. The sizes of the amplicons were assessed by loading the PCR products on 
an ethidium bromide-stained 1.5% agarose gel analyzed under ultraviolet light. Standard 
curves were generated for each transcript demonstrating 90-100% amplification efficiency. 
Relative quantification of gene expression was determined by comparison of threshold 
values. All results were normalized to glyceraldehyde-3-phosphate dehydrogenase which 
varied neither with overexpression nor silencing of p53. To exclude amplification of GAPDH 
pseudogenes, previously described GAPDH-specific primer sequences were used.27 All qRT-
PCR primers were purchased from Sigma-Aldrich. 
Primer sequences were (forward, reverse): 
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BAI1:  5'-GCAAACCAAGTTCTGCAACAT-3', 5'-CTCCAGCTCGACCACTCATT-3'; 
bFGF:  5'-AGCGGCTGTACTGCAAAAAC-3', 5'-TGCTTGAAGTTGTAGCTTGATGT-
3'; 
GAPDH:  5'-CTCTCTGCTCCTCCTGTTCGAC-3', 5'-TGAGCGATGTGGCTCGGCT-3'; 
P4HA1: 5'-GGCAGCCAAAGCTCTGTTA-3', 5'-AGTCCTCAGCCGTTAGAAAAGA-3'; 
P4HA2: 5'-AGCGGCTAAACACAGACTGG-3', 5'-GGCAGCTCCTATCTCGTCCT-3'; 
p21CIP1/WAF1: 5'-TCACTGTCTTGTACCCTTGTGC-3', 5'-GGCGTTTGGAGTGGTAGAAA-3'; 
p53:   5'-CCTGCCCTCAACAAGATGTT-3', 5'-CCACTCGGATAAGATGCTGA-3'; 
TSP1:  5'-CAATGCCACAGTTCCTGATG-3', 5'-TGGAGACCAGCCATCGTC-3'; 
VEGF:  5'-TCTTCAAGCCATCCTGTGTG-3', 5'-GGTGAGGTTTGATCCGCATA-3'. 
 
P4HA2 promoter analysis 
For sequence analysis of the P4HA2 promoter region, genomic DNA was extracted from 
H1299 and LN-308 cells using the QIAamp DNA Mini Kit (Qiagen) according to the 
manufacturer’s instructions. Genomic DNA spanning 1470 bp of the P4HA2 promoter region 
(-1141 to +329, relative to the transcription start site) covering the three putative p53-binding 
half sites at positions -442 to -450, -449 to -457 and -458 to -46724 was amplified as two 
partially overlapping DNA fragments, 550 base pairs (bp) and 990 bp of length, by 
polymerase chain reaction (PCR) using the following PCR primer pairs (forward, reverse):  
5'-CAGGGGTCGCAGAGGACGGC-3', 5'-CCCGGGAGCCTGACAGGGAA-3'; 
5'-CTTCGTGCAGTTCCCTCGGC-3', 5'-TTGGCTCACTGCAACCTCTGCCTCC-3'. 
Using the same primers, both strands of each PCR product were sequenced, aligned and 
analyzed for mutations by comparison with the data base entry for the P4HA2 5' flanking 
sequences and exon 1.28 
Methylation-specific PCR (MSP) was used to analyze the p53-binding sites within the P4HA2 
promoter region for potential methylation-mediated epigenetic silencing. One µg of genomic 
DNA derived from LN-308 or LNT-229 cells was treated with sodium bisulfite using the 
Qiagen EpiTect Kit (Qiagen) with the provided protocol. The primer sequences used to 
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detect methylated P4HA2 promoter sequences were 5′-
TGGTCGTTTTTTTTTGTTAGGTTTTC-3′ and 5′-CGCAACTACCAAAAAAAAACAACG-3′. 
The primer sequences used to detect unmethylated P4HA2 promoter sequences were 5′-
GGTTGTTTTTTTTTGTTAGGTTTTTG-3′ and 5′-CCACAACTACCAAAAAAAAACAACA-3′. 
Both primer combinations amplify 271 bp fragments from methylated and unmethylated DNA, 
respectively. After an initial denaturation step at 95°C for 10 min, 38 PCR cycles were run 
using the following conditions: denaturation, 94°C for 30 s; annealing, 60°C for 60 s; 
extension, 72°C for 55 s; followed by a final extension at 72°C for 10 min. As positive or 
negative controls for methylation, CpGenome Universal Methylated or Unmethlated DNA, 
Vial A, (Millipore, Temecula, CA, USA) were used. In addition, a control reaction without any 
template DNA was performed for both PCR experiments. The PCR products were separated 
on a 3% agarose gel, extracted from the gel and sequenced with the respective primer pair 
used in the MSP. MSP primers were purchased from Eurofins MWG Operon (Ebersberg, 
Germany). 
 
Immunoblot 
Immunoblots were performed as described.29 Briefly, cell lysates were prepared in 50 mM 
Tris-HCl (pH 8.0) containing 120 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 2 mg/ml 
aprotinin, 10 mg/ml leupeptin and 100 mg/ml phenylmethylsulfonyl fluoride. 20 µg aliquots of 
cell lysates were electrophoresed on 10% SDS-PAGE gels under reducing conditions and 
subsequently transferred onto a nitrocellulose membrane (Bio-Rad, Munich, Germany) in all 
cases except for c-P4HA1 that was blotted using PVDF membranes (Millipore, Schwalbach, 
Germany). After blocking nonspecific-binding sites in 5% (w/v) dried milk in TBS containing 
0.1% tween for 2 h, membranes were incubated with specific primary antibodies towards 
p53, p21CIP1/WAF1, c-P4HA1 or P4HA2 overnight at 4°C, washed and incubated with the 
respective horseradish peroxidase-conjugated secondary antibody for 1 h at room 
temperature. Equal protein loading was ascertained by detecting expression of 
housekeeping genes (GAPDH, actin, or -tubulin) accordingly. Protein bands were visualized 
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using Enhanced Chemiluminescence Plus (GE Healthcare UK Limited, Buckinghamshire, 
UK). 
The following antibodies were used: 
Actin: anti-actin goat polyclonal antibody (pAb) (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), 0.2 µg/ml; 
GAPDH:  anti-GAPDH goat pAb (abcam, Cambridge, UK), 1:1,000; 
P4HA1: whole serum from guinea pig immunized with P4HA1 peptide (gift from 
Tore Kempf, PhD, German Cancer Research Center, Heidelberg, 
Germany), 1:5,000; 
P4HA2:  anti-P4HA2 rabbit pAb (Bethyl Laboratories, TX, USA), 2.0 µg/ml; 
p21CIP1/WAF1: anti-p21CIP1/WAF1 mouse monoclonal antibody (mAb) (Merck), 0.1 mg/ml; 
p53:   anti-p53 mouse mAb (Merck, Darmstadt, Germany), 1 µg/ml; 
-tubulin:  anti--tubulin mouse mAb (Sigma), 1:5,000; 
anti-goat:  peroxidase-conjugated donkey anti-goat (Invitrogen), 0.4 µg/ml; 
anti-guinea pig:  peroxidase-conjugated goat anti-guinea pig (Jackson 
ImmunoResearch, Suffolk, UK), 0.16 µg/ml; 
anti-mouse: peroxidase-conjugated sheep anti-mouse (GE Healthcare UK Limited), 
1:5,000; 
anti-rabbit: peroxidase-conjugated donkey anti-rabbit (GE Healthcare UK Limited), 
1:2,000. 
 
Endostatin enzyme-linked immunosorbent assay 
For the quantitative determination of human endostatin concentrations, serum-free 
glioblastoma cell-conditioned supernatants supplemented with 100 µM ascorbic acid (Sigma-
Aldrich) were freed from cellular debris, nonadherent and dead cells by centrifugation (3 min; 
4,370 g) and subjected to a solid-phase enzyme-linked immunosorbent assay specific for 
human endostatin (Quantikine® Human Endostatin Immunoassay, R&D Systems, 
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Minneapolis, MN, USA). Duplicates of each sample were examined according to the 
manufacturer’s protocol. 
 
In vitro angiogenesis assays 
Conditioned supernatants derived from adherent LN-308, LNT-229 and H1299 tumor cells 
were tested in functional in vitro angiogenesis paradigms. LN-308 glioma cells, 8 h after 
transient transfection with p53 wild-type or control plasmids, p53-silenced LNT-229 cells and 
LN-308 or H1299 cells stably overexpressing P4HA2, following adherence overnight, were 
washed in PBS and cultured in endothelial cell basal medium (ECBM) including 1 µM Fe(III) 
(Promocell) supplemented with 100 µM ascorbic acid without FBS or antibiotics for 48 h. For 
hCMEC viability, DMEM was used instead of ECBM. Supernatants were collected and freed 
from debris, nonadherent and dead cells by centrifugation (3 min; 4,370 g), supplemented 
with 2-10% FBS and recombinant VEGF (R&D Systems) at 25 ng/ml, and tested in the in 
vitro angiogenesis assays described below (a-c). Recombinant human endostatin 
(Calbiochem, Darmstadt, Germany) at 10 µg/ml compared with its vehicle control (66 mM 
sodium phosphate, 59 mM sodium chloride, 17 mM citric acid, pH 6.2) diluted in ECBM 
served as a positive control in all in vitro angiogenesis experiments. 
a) HUVEC sprouting assay. Spheroid formation and sprouting of HUVEC was carried out as 
described previously.30,31 In brief, spheroids were generated by resuspending 400 HUVEC 
per spheroid in 25 µl culture medium containing 0.24% (w/v) carboxymethylcellulose (Sigma-
Aldrich) followed by an incubation for 24 h as hanging drops. After 24 h, spheroids were 
embedded into collagen gels. A collagen stock solution was prepared prior to use by mixing 
8 volumes collagen (rat tail collagen equilibrated to 2 mg/ml in 0.1% acidic acid) with 1 
volume Medium 199 (Sigma-Aldrich), ~1 volume 0.2 M NaOH to adjust pH to 7.4 and 1 M 
HEPES buffer (Roth, Karlsruhe, Germany) at a final dilution of 1:50. Fifty HUVEC spheroids 
were resuspended into a collagen gel consisting of 0.5 ml collagen stock solution mixed with 
0.5 ml medium (ECBM including 20% FBS) containing 0.5% (w/v) carboxymethylcellulose to 
prevent sedimentation of spheroids prior to polymerization. One ml per well of the spheroid-
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containing gel was rapidly transferred into a 24-well plate prewarmed to 37°C and allowed to 
polymerize for 30 min. One hundred µl of glioblastoma cell-conditioned supernatant were 
then pipetted on top of each gel. After incubation for 24 h, in vitro angiogenesis was digitally 
quantitated by measuring the lengths of the sprouts grown out of each spheroid with an 
ocular grid at 100x magnification using Image J (http://rsbweb.nih.gov/ij/index.html). At least 
30 spheroids per experimental group and experiment were analyzed. The average 
cumulative sprout length of all spheroids belonging to one treatment group was calculated. 
b) Cell viability assay. Endothelial cell viability assays were performed using both HUVEC 
and hCMEC. Cells were seeded into 96-well plates at 2,000 cells suspended in 100 µl growth 
medium. After attachment (~ 8 h), endothelial cells were starved for 16 h by replacing the 
growth medium with ECBM (for HUVEC) or DMEM (for hCMEC) containing 2% FBS. 
Following starvation, endothelial cells were incubated in 100 µl of tumor cell-derived 
supernatant for 96 h conditioned as described above. Absorbance of viable endothelial cells 
was colorimetrically measured in a 96-well plate reader (Thermo Scientific, Karlsruhe, 
Germany) at 490 nm using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) as a substrate provided in the CellTiter 96® Aqueous One 
Solution Cell Proliferation Assay (Promega, Madison, WI, USA) following the manufacturer’s 
recommendations. Each supernatant was tested in triplicates. 
c) HUVEC transmigration assay. HUVEC transmigration assays were performed in 6.5 mm 
Transwells® with gelatine-coated 8.0 µm pore polycarbonate membrane inserts (Corning 
Incorporated, Lowell, MA, USA). These inserts were placed into 24-well plates containing 
600 µl glioma cell supernatants conditioned as described above and supplemented with 
VEGF as chemoattractant. HUVEC were seeded at 105 cells suspended in 100 µl of the 
same supernatants without VEGF on top of each membrane into the upper chamber. Cells 
were allowed to migrate through the pores for 4 h, fixed with ice-cold methanol and stained 
with Hoechst dye (Sigma-Aldrich). Migrated cells were counted after removal of non-migrated 
cells from the upper surface of the membrane using a cotton swab. Quantitation was 
performed using the particle analysis Cell-F software (Olympus, Hamburg, Germany) by 
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counting labeled cells within seven high-power fields at 100-fold magnification. Each 
supernatant was tested in triplicates. 
 
Statistical analysis 
Quantitative data obtained for vessel quantitations, qRT-PCR, ELISA and in vitro 
angiogenesis assays are expressed as mean +/- standard deviation, as indicated. Statistical 
analyses were performed using Student’s t-test (Excel, Microsoft, Seattle, WA, USA). Values 
of p < 0.05 were considered significant and marked with an asterisk. 
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Results 
The TP53 Mutational Status Does Not Affect Tumor Angiogenesis in Primary Glioblastoma 
Wild-type p53 has been reported to be associated with suppressed angiogenesis in human 
tumors and cancer cell lines originating from different tissues.24,32-35 Based on these previous 
findings, we intended to assess the potential value of p53 as a molecular marker to indicate 
the extent of vascularization in glioblastoma. To this end, we selected formalin-fixed, paraffin-
embedded tissues of 40 newly diagnosed, treatment-naïve glioblastoma specimens. Though 
mutations in the TP53 gene are observed more frequently in secondary than in primary 
glioblastomas,36 we focused our study exclusively on newly diagnosed glioblastomas thereby 
avoiding that potential therapy-induced genetic and tissue alterations bias our findings. IDH1 
mutations have recently been identified as a marker for the genetic profile of secondary 
glioblastomas.37 To exclude glioblastomas with the genetic profile of secondary 
glioblastomas we screened for the most frequent IDH1 mutation (R132H) using the IDH1 
mutation-specific antibody mIDH1R132H as recently described.22 In this set of primary 
glioblastomas, we determined the TP53 mutational status by sequence analysis of exons 5 
to 8. In four cases, DNA quality was too low to perform sequence analysis. One case was 
excluded because of positive immunoreactivity with mIDH1R132H. In the remaining cases, 
we identified 26/35 (74%) TP53 wild-type (p53wt) and 9/35 (26%) TP53 mutated (p53mut) 
specimens (see Table 1 for details). For standardization, automated image analysis of CD31-
positive vascular structures was performed in solid tumor tissue distant from necroses within 
regions of highest tumor proliferation. Representative examples of analyzed tumor regions 
are given in Fig. 1A. As a result, neither total area nor total number of vascular structures 
differed significantly between p53wt and p53mut glioblastomas (Fig. 1B and C; p = 0.31 and 
p = 0.4, respectively).  
 
P4HA2 Is Transcriptionally Activated through p53 in Glioblastoma Cells 
The results from these comparative analyses demonstrated a lacking correlation between the 
TP53 mutational status and the extent of vascularization in primary glioblastoma. As these 
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observations seemed to conflict in part with data from the literature attributing an 
angiogenesis-regulating function to p53,24,33 we next investigated whether factors encoded by 
p53-dependent target genes that have been described previously to be involved in controlling 
angiogenesis of various malignancies were functional in glioblastoma cells. This literature-
guided candidate approach comprised the two proangiogenic molecules VEGF35 and bFGF38 
and the three antiangiogenic factors TSP1,39 BAI1,34 and P4HA2.24 We overexpressed wild-
type p53 in the human glioblastoma cell line LN-308 that natively expresses no p53 protein 
due to a homozygous deletion of the TP53 gene (p53-/-),23 and checked p53-dependent 
transcription of the aforementioned angiogenesis-associated factors by qRT-PCR (Fig. 2A). 
We confirmed wild-type activities of p53 (Fig. 2A, upper left panel) in that it was able to 
upregulate the levels of mRNA for the known p53-responsive downstream target gene, 
p21CIP1/WAF1 (Fig. 2A, upper right panel).40 As opposed to all other candidate transcripts 
included in our study, only mRNA for P4HA2 was significantly induced by overexpression of 
wild-type p53. By contrast, expression of wild-type p53 had no effect on transcription of 
another collagen prolyl-4-hydroxylase isoform, P4HA1 (Fig. 2A, lower panel). 
Based on these observations, we focused our study hence on the role of P4HA2 in regulating 
glioblastoma angiogenesis. The P4HA2 gene encodes a component of a collagen prolyl 4-
hydroxylase, a key enzyme in collagen biosynthesis composed of two identical alpha 
subunits and two beta subunits. P4HA2 provides the major part of the catalytic site of the 
active enzyme that catalyzes, in collagen and related proteins, the formation of 4-
hydroxyproline being essential to the proper three-dimensional folding of newly synthesized 
procollagen chains. While the second rate-limiting enzyme of collagen biosynthesis, P4HA1, 
is ubiquitously expressed and represents the major isoform in connective tissues, P4HA2 is  
expressed in a more restricted manner in chondrocytes and endothelial cells.41 Aside from 
p53-/- Saos-2 osteosarcoma cells, transcriptional activation of P4HA2 through stimulation of 
endogenous wild-type p53 or gene transfer of wild-type p53 was first described for the 
human p53-/- non-small cell lung carcinoma cell line H1299. In these cells, P4HA2 induction 
by wild-type p53 resulted in increased synthesis and secretion of full-length collagens 18 and 
  Berger et al.  
  17
4, which were proteolytically processed in the extracellular matrix to produce respective C-
terminal antiangiogenic peptides, endostatin and tumstatin, leading to reduced angiogenesis 
in vitro and in vivo.24 
We first confirmed the p53-responsiveness of P4HA2 in H1299 carcinoma cells (Fig. 2B) and 
included them as positive controls in further experiments with glioblastoma cells. To foster 
our findings from LN-308 cells, we used, as an additional model, the p53wt glioblastoma cell 
line LNT-229 in which expression of p53 was silenced by single hairpin RNA (shRNA) 
technology.23 The resulting knock-down of p53, as controlled by proving reduced expression 
of p21CIP1/WAF1, was paralleled by a decrease in the transcription of P4HA2, but not of P4HA1 
(Fig. 2B). Conversely, up-regulation of P4HA2, but not of P4HA1, was observed when 
endogenous p53 expression was pharmacologically induced in a concentration-dependent 
manner in LNT-229 cells by applying the DNA damage-inducing topoisomerase I inhibitor 
camptothecin.42 Again, p53-mediated, concentration-dependent induction of p21CIP1/WAF1 in 
response to camptothecin served as an internal positive control in this model (Fig. 2B). 
Sequence analysis of the promoter region of the P4HA2 gene revealed a CpG site at position 
-458/-457 critically located between two of three putative neighboring p53-binding half sites 
ranging from position -467 to -442 relative to the transcription start site (Fig. 2C, upper 
panel).24 As methylation of this CpG site might interfere with the transcriptional efficiency of 
the P4HA2 mRNA, we performed methylation analyses of this promoter region using 
bisulfite-treated genomic DNA from LN-308 and LNT-229 cells analyzed by methylation-
specific polymerase chain reaction (MSP, Fig. 2C, middle panel) and methylation-specific 
sequencing (Fig. 2C, lower panel). As a result, we found that CpG site to be unmethylated 
showing that p53-induced transcriptional activation of P4HA2 would not be affected by 
methylation-mediated promoter silencing in glioblastoma cells. 
 
p53-Dependent Antiangiogenic Signaling via P4HA2 Is Defective in Glioblastoma Cells 
Our results from LN-308 and LNT-229 glioblastoma cells suggested that, of the 
angiogenesis-related factors examined in our study, only P4HA2 was transcriptionally 
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controlled by wild-type p53. Hence, it seemed consequent to figure out whether p53-induced 
mRNA levels of P4HA2 translated into an increase of biologically active P4HA2 enzyme and 
thus enhanced production of functionally relevant antiangiogenic collagen fragments. 
Unexpectedly, despite its transcriptional activation, ectopic overexpression of wild-type p53 
in p53-/- LN-308 cells did not lead to induced protein levels of P4HA2 (Fig. 3A, left panel). 
Consistently, p53-silencing in p53wt LNT-229 cells did not lead to a decrease of P4HA2 
protein (Fig. 3A, middle panel), and camptothecin-mediated induction of endogenous p53 did 
not upregulate P4HA2 protein either (Fig. 3A, right panel). Wild-type activities of p53 were 
verified in all immunoblots by proving the regulation of p21CIP1/WAF1 protein (Fig. 3A). We next 
tested whether overexpression of wild-type p53 in p53-/- LN-308 cells or p53-silencing in 
p53wt LNT-229 cells had an effect on extracellular concentrations of the antiangiogenic 
collagen 18 fragment endostatin using an endostatin-specific enzyme-linked immunosorbent 
assay (ELISA). We found concentrations of endostatin in supernatants of both glioblastoma 
cell lines were not altered by manipulating the expression levels of p53 compared with the 
respective controls (Fig. 3B). Consistent with these results, supernatants derived from p53-
overexpressing LN-308 cells or p53-silenced LNT-229 cells did not influence endothelial cell 
function as examined in three independent in vitro angiogenesis assays: (i) sprouting of 
primary human umbilical vein endothelial cells (HUVEC) (Fig. 3C), (ii) cell viability of HUVEC 
and human cerebral microvascular endothelial cells (hCMEC) (Fig. 3D), and (iii) 
transmigration of HUVEC (Fig. 3E). As it has long been recognized to inhibit multiple 
endothelial cell functions,43,44 recombinant human endostatin served as a positive control in 
each angiogenesis assay (Fig. 3C-E).  
In summary, the results from all three in vitro angiogenesis assays mirror the overall effect of 
wild-type p53 expressed in glioblastoma cells on endothelial cell function irrespective of 
underlying signaling mechanisms. In this regard, these data make clear that potentially p53-
associated and angiogenesis-related mechanisms that would even be independent from 
P4HA2- and collagen-dependent signaling are inefficient in modifying endothelial cell 
function. After all, these data are in line with our results from the comparative vessel 
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quantitations in p53wt and p53mut primary glioblastoma specimens (Fig. 1) that also failed to 
show a difference. 
 
p53-Independent P4HA2 Antiangiogenic Signaling through Endostatin Is Functional in 
Carcinoma but Not in Glioblastoma Cells 
If, in glioblastoma cells, p53 does not trigger P4HA2-mediated production of antiangiogenic 
collagen fragments such as endostatin, then ectopic overexpression of P4HA2 should clarify 
whether antiangiogenic signaling downstream of P4HA2 is functional even in the absence of 
p53. To pursue this question, we generated stably P4HA2-overexpressing p53-/- LN-308 cells 
(Fig. 4A) and compared derived extracellular endostatin concentrations with control-
transfected LN-308 cells. As opposed to H1299 lung carcinoma cells that showed a marked 
increase of extracellular endostatin leading to reduced HUVEC survival, LN-308 glioblastoma 
cells responded to p53-independent overexpression of P4HA2 neither with induced 
endostation production (Fig. 4B) nor with differential effects on endothelial function in vitro as 
measured by HUVEC viability (Fig. 4C). Thus, uncoupling of p53 and P4HA2 action still 
failed to restore the antiangiogenic program that seems to be functional in carcinoma cells. In 
summary, these data suggest that, in glioblastoma cells, p53-controlled antiangiogenic 
signaling through P4HA2, collagens and their proteolytically derived C-terminal fragments is 
shut down both at the translational and the post-translational level. 
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Discussion 
With the present study, we demonstrate that (i) the tumor suppressor protein p53 does not 
have an impact on vascularization in glioblastomas and (ii) the reason for this is that, in these 
tumors, wild-type p53-dependent antiangiogenic signaling pathways known to be functional 
in other malignancies are shut down either at the transcriptional or the 
translational/posttranslational level.  
We included two genetically different human glioblastoma cell lines in our in vitro studies and 
applied three independent modes of regulating p53 activity in these cells: (i) ectopic 
overexpression of wild-type p53 in a homozygously p53-deleted genetic background (LN-308 
and H1299 cells); (ii) shRNA-mediated silencing of wild-type p53 function (LNT-229 cells); 
and (iii) pharmacological induction (camptothecin) of endogenous wild-type p53 activity 
(LNT-229 cells). We then compared conditioned supernatants derived from these tumor cell 
lines in functional assays testing for human endothelial cell sprouting, viability and 
transmigration. Aside from otherwise commonly used human umbilical vein endothelial cells 
(HUVEC), we integrated human cerebral microvascular endothelial cells (hCMEC) in these 
studies as they appeared likely to be more meaningful for investigations of angiogenesis in 
cerebral tumors. Guided by precedent reports from the literature, we analyzed the p53-
dependent transcriptional inducibility of five candidate genes implicated in angiogenesis: 
VEGF,35 bFGF,38 TSP1,39 BAI1,34 and P4HA2,24 and concluded that of these, only P4HA2 
was transcriptionally activated through wild-type p53 (Fig. 2A). This collagen prolyl 
hydroxylase isoform was first described by Teodoro et al. as a genetic and biochemical 
linkage between the p53 tumor suppressor pathway and the synthesis of antiangiogenic 
collagen fragments, e.g., endostatin and tumstatin, in various cancer cell lines including 
H1299 lung carcinoma cells.24 We hence focused on this signaling pathway and found that, 
despite the p53-dependent induction of its transcript, the amounts of P4HA2 protein turned 
out not to vary in response to altering p53 activities in glioblastoma cells suggesting a 
translational blockade (Fig. 3A). In this context, another isoform of the protein family of 
collagen prolyl hydroxylases, P4HA1, has been reported to be translationally dependent on 
  Berger et al.  
  21
two chaperon molecules, nucleolin and annexin A2, when cells were exposed to hypoxia.45 It 
is thus conceivable that wild-type p53 acivates transcription of the P4HA2 isoform without 
leading to increased protein amounts due to reduced mRNA stability in the absence of 
required chaperones. 
However, even stable overexpression of P4HA2 in glioblastoma cells independent from p53 
activities (Fig. 4A) was neither paralleled by induced extracellular endostatin levels (Fig. 4B) 
nor by altered endothelial functions (Fig. 4C) suggesting at least one additional 
posttranslational blockade in this pathway. The processing of full length collagen 18 into 
biologically active endostatin is a complex process that involves several matrix 
metalloproteinases (MMP)46 as well as cathepsin L and elastase.47-49 Regarding our results, it 
is possible that, in addition to translationally blocked P4HA2, a further step needed for the 
maturation and processing of collagen molecules to antiangiogenic C-terminal fragments is 
defective in glioblastoma cells. 
Besides collagen-derived endostatin or tumstatin, other secretory factors have been reported 
to regulate angiogenesis in a p53-dependent manner in various cancers.19 To our 
knowledge, however, the undisputed identification and characterization of such a factor in 
malignant gliomas is pending. Brain-specific angiogenesis inhibitor 1 (BAI1) was identified as 
a promising antiangiogenic candidate in a library screen for p53-regulated genes in glioma.34 
BAI1 contains vasculostatin, a proteolytic fragment of its extracellular domain, with known 
antiangiogenic properties.50 A subsequent study, however, that evaluated the relationship 
between p53 and BAI1 more thoroughly concluded that expression of BAI1 is independent 
from p53 activity. Consistent with this later work, we did not observe BAI1 to be 
transactivated by wild-type p53 in LN-308 cells (Fig. 2A), and BAI1-specific mRNA levels 
were proved to be absent in LNT-229 cells (data not shown). 
Yet conflicting with our observations are data from an early work in this field describing an 
angiogenesis-suppressing function of wild-type p53 upon Tet-mediated conditional induction 
in one p53-deficient glioblastoma cell line, LN-Z308, using in vitro bovine adrenal gland 
capillary endothelial cell migration assays and in vivo neovascularization experiments in rat 
  Berger et al.  
  22
corneas as functional read-outs. The authors of that work postulated the existence of a 
secretory angiogenesis-suppressing factor released from wild-type p53 glioblastoma cells 
which they tentatively called glioma-derived angiogenesis inhibitor factor (GD-AIF).33 Albeit 
based on different experimental setups that might, at least in part, explain the difference to 
our results, that work did not provide tissue-based proofs corroborating the preclinical 
findings in glioblastoma cells. Proofs for a negative correlation between expression of wild-
type p53 and tumor vascularization based on patient-derived tumor specimens are indeed 
documented for a variety of epithelial cancers including non-small cell lung, colorectal, 
breast, prostate, and esophageal carcinomas.15,16,51-53 By contrast, in some gynecologic 
malignancies, i.d. epithelial ovarian and endometrial cancers, such a correlation was not 
observed.54,55 Together with our results that confirmed the p53/P4HA2-mediated 
antiangiogenic pathway in a carcinoma cell line, H1299, it seems therefore likely that effects 
of p53 on tumor angiogenesis are cell or tumor type-specific. 
Of note, a recently published work described increased microvessel densities and absolute 
vessel numbers in a set of TP53-mutated diffuse low-grade astrocytoma specimens when 
compared with their TP53 wild-type counterparts suggesting that p53 exerts an 
angiogenesis-suppressing function in low-grade gliomas.56 It might thus be tempting to 
speculate that the influence of p53 on glioma angiogenesis declines during the course of 
malignant transformation and that this might contribute to the angiogenic switch. This 
assumption would be in line with the notion that, in contrast to most carcinomas, in which p53 
mutations occur late during tumor progression, p53 mutations represent an early event in the 
progression of gliomas.57,58 By contrast, pathological angiogenesis is a late event during 
glioma progression that primarily characterizes the phenotype of glioblastomas.59 Tumor cells 
lacking wild-type activities of p53 are genetically unstable and thus prone to accumulating 
additional molecular alterations enhancing the neoplastic phenotype including increased 
neovascularization. In addition, hypoxia becomes increasingly influential during tumor 
progression subsequently leading to the stabilization of HIF-1 (and HIF-2) and the 
expression of proangiogenic target genes, e.g., VEGF. Hypoxia, in turn, has been 
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demonstrated to select for tumor cells with diminished apoptotic potential, e.g., due to loss of 
wild-type p53 function, in solid tumors.60 Being aware of the fact that the frequency of 
mutations in the TP53 gene is lower in primary (28%) than in secondary glioblastomas 
(65%), our study consistently focuses on the role of p53 in affecting angiogenesis in newly 
diagnosed, i.e. treatment-naïve, glioblastomas primarily in order to circumvent the potential 
bias caused by therapy-induced genetic and tissue alterations.20 
Remarkably, molecular alterations in tumor cells, e.g. the presence or absence of functional 
p53, leading to their genetic instability and thus resistance towards apoptosis influence the 
response of adjacent (genetically stable) endothelial cells in the tumor vasculature 
representing the virtual target of antiangiogenic agents. Hints that p53 is not only 
instrumental in regulating tumor angiogenesis but also potentially predictive for responding to 
antiangiogenic therapy come from studies in mice bearing tumors derived from TP53-/- 
HCT116 human colorectal carcinoma cells that proved to be less responsive to 
antiangiogenic therapy than mice bearing isogenic TP53+/+ tumors.61 p53 being well-
established in neuropathological diagnostics could thus have been an attractive novel 
biomarker of angiogenesis and predictor of response to antiangiogenic treatment in high-
grade gliomas, particularly given that a number of promising antiangiogenic and vasculature-
modifying agents are currently under investigation for these tumors.62 In a recently published 
translational study conducted by the German Glioma Network analyzing 301 prospectively 
accrued patients with newly diagnosed glioblastomas, neither TP53 mutations nor p53 
immunoreactivity turned out to be of prognostic or predictive value for primary glioblastomas 
treated according to current standards of care.21 Our findings extend this perception in that 
they challenge the view of p53 as an angiogenesis-regulating factor in glioblastoma and 
hence question its potential predictive value for any antiangiogenic regimen applied in this 
tumor entity. 
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Table 1. TP53 mutations (exons 5 to 8) identified in 9 of 35 primary glioblastomas. Het, 
heterozygous. 
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Specimen No. Exon  Mutation Amino Acid Substitution Mutation Type  
2 8 C817T het R273C missense 
5 8 G818A het R273H missense 
16 5 G524A het R175H missense 
19 7 A701G het Y234C missense 
21 6 T658C het Y220H missense 
22 6 C665T het P222L missense 
25 6 636-637 delTT  Frameshift leads to stop codon 214  nonsense  
30 8 C844T het R282W missense 
33 8 G841T het  D281Y missense 
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Figure legends 
Fig. 1. The extent of vascularization in primary glioblastomas is independent from the TP53 
mutational status. (A) Photomicrographs of CD31-stained primary glioblastoma specimens 
carrying either the TP53 wild-type (TP53wt) or TP53 mutated (TP53mut) gene. Micrographs 
were subjected to automated image analyses. The left panel shows a representative TP53wt 
tumor (specimen 3), the right panel represents a TP53mut tumor (specimen 25). 
Magnification 100-fold. (B and C) Vessel quantitation in TP53wt and TP53mut primary 
glioblastoma specimens depicted as total area of vascular structures as percentage of total 
analyzed tumor region (B, p = 0.31), and total number of vascular structures (C, p = 0.4). 
Data are mean ± standard deviation. 
 
Fig. 2. p53 activates transcription of P4HA2 in glioblastoma cells. (A) Expression levels of 
p53 (upper left panel), p21CIP1/WAF1 (upper right panel) and mRNAs of several proangiogenic 
(VEGF and bFGF) and antiangiogenic (TSP1, BAI1, P4HA2) factors plus P4HA1 (lower 
panel) measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 
in homozygously TP53-deleted (p53-/-) LN-308 glioblastoma cells following transfection with a 
p53-encoding expression vector (p53) or the empty vector as a control (Ctrl.). (B) QRT-PCR-
measured expression levels of p53 (upper panel), p21CIP1/WAF1 (upper middle panel), P4HA2 
(lower middle panel) and P4HA1 (lower panel) mRNAs in the p53-/- H1299 lung carcinoma 
cell line transfected as LN-308 cells in (A), in p53-silenced (p53sh) or control (Ctrl.) LNT-229 
glioblastoma cells (TP53 wild type, p53wt), and in LNT-229 cells treated with increasing 
concentrations (1, 10 and 100 nM) of camptothecin or dimethyl sulfoxide as a vehicle control 
(0 nM). GAPDH-normalized expression of each transcript in (A) and (B) is expressed relative 
to control conditions set as 1. Data are mean ± standard deviation. *, p < 0.05. Experiments 
were repeated three times with similar results. (C) Methylation analysis of the P4HA2 
promoter region.24 Upper panel, schematic diagram of the P4HA2 promoter region from 
position -467 to -442  showing the positions of the putative partially overlapping p53-binding 
half sites at positions -442 to -450, -449 to -457 and -458 to -467, as indicated with brackets, 
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and the genomic and deduced bisulfite DNA sequences in case of methylation (a) or not (b) 
including the critical CpG site at position -458/-457 (marked by red rectangle) relative to the 
transcription start site. Middle panel, methylation-specific polymerase chain reaction (MSP) 
products at 271 base pairs (bp) using bisulfite-treated genomic DNA derived from LN-308 
and LNT-229 glioblastoma cells as a template and primer pairs specific for annealing to 
methylated (M) and unmethylated (U) bisulfite DNA. CpGenome Universal Methylated (Meth) 
or Unmethlated (Unmeth) DNA (Millipore, Temecula, CA, USA) served as positive or 
negative controls for both primer pairs. A control reaction without any template DNA (H2O) 
was included as an additional negative control. PCR products were separated on a 3% 
agarose gel. First lane left, 100 bp DNA marker. Lower panel, methylation-specific sequence 
of bisulfite-treated DNA of the P4HA2 promoter region (position -467 to -442) in LN-308 and 
LNT-229 cells. The methylation status of the critical CpG site at position -458/-457 is marked 
by a red square corresponding to the deduced bisulfite DNA sequence depicted in the upper 
panel. TSS, transcription start site. 
 
Fig. 3. p53-dependent antiangiogenic signaling via P4HA2 is defective in glioblastoma cells. 
(A) Immunoblot analyses demonstrating expression of p53, p21CIP1/WAF1, P4HA2 and P4HA1 
proteins in human glioblastoma cell lines. Left panel, lysates of homozygously TP53-deleted 
(p53-/-) LN-308 cells transiently transfected with an expression vector containing either p53-
encoding (p53) or no insert cDNA (Ctrl.). Middle panel, lysates of TP53 wild-type (p53wt) 
LNT-229 cells stably transfected with a p53-silencing plasmid (p53sh) or an empty control 
plasmid (Ctrl.), respectively. Right panel, lysates of LNT-229 cells treated with increasing 
concentrations (1, 10 and 100 nM) of camptothecin or with dimethyl sulfoxide as a vehicle 
control (0 nM). Actin, GAPDH and -tubulin served as loading controls. (B) Enzyme-linked 
immunosorbent assay (ELISA)-based quantitation of endostatin concentrations in 
conditioned supernatants of LN-308 and LNT-229 cells transfected as in (A). (C)-(E) In vitro 
angiogenesis assays testing conditioned supernatants derived from either p53-
overexpressing LN-308 cells (LN-308/p53), p53-silenced LNT-229 cells (LNT-229/p53sh) or 
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control cells as in (A) for HUVEC sprouting (C), HUVEC and hCMEC viability (D), and 
HUVEC transmigration (E). Treatment with 10 µg/ml recombinant human endostatin (rhEndo) 
served as a positive control in each assay. Responses of HUVEC and hCMEC towards 
supernatants from p53-overexpressing and p53-silenced glioblastoma cells or recombinant 
endostatin is expressed relative to supernatants derived from respective control cells or the 
vehicle for endostatin set as 100%. Data are mean ± standard deviation. *, p < 0.05. 
Experiments were repeated three times with similar results. Insets depict representative 
endothelial cell responses towards the respective treatment as indicated. Scale bars, 100 
µm. 
 
Fig. 4. p53-uncoupled P4HA2-mediated antiangiogenic signaling through endostatin is 
functional in carcinoma but not in glioblastoma cells. (A) Immunoblot analysis confirming 
overexpression of P4HA2 protein in both p53-/- H1299 lung carcinoma (left panel) and p53-/- 
LN-308 glioblastoma cells (right panel) following stable transfection with an expression vector 
encoding P4HA2 (P4HA2) and an empty vector (Ctrl.), respectively. -tubulin or GAPDH 
served as loading controls. (B) ELISA-based quantitation of endostatin concentrations in 
conditioned supernatants of either H1299 or LN-308 cells transfected as in (A). (C) Viability 
of HUVEC exposed to conditioned supernatants from either H1299 or LN-308 cells 
transfected as in (A). HUVEC viability at exposure to supernatants derived from P4HA2-
overexpressing tumor cells is expressed relative to supernatants from empty vector controls 
set as 100%. Data are mean ± standard deviation. *, p < 0.05. Experiments were repeated 
three times with similar results. 
 
